Reduced Plasma Dopamine-β-Hydroxylase Activity Is Associated With the Severity of Bipolar Disorder: A Pilot Study.

bipolar disorder cognitive function dopamine-β-hydroxylase major depressive disorder mood disorder

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2021
Historique:
received: 27 05 2020
accepted: 29 03 2021
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 18 5 2021
Statut: epublish

Résumé

Dopamine-β-hydroxylase (DβH) is an enzyme converting dopamine to norepinephrine, a key neurotransmitter in mood disorders, such as major depressive disorder (MDD) and bipolar disorder (BD). Due to overlapping symptomology of unipolar and bipolar depression, the present study attempted to explorer if the plasma DβH activity could discriminate the depressive episodes of BD from MDD. The aim of this study was to compare the plasma DβH activity among MDD patients (

Identifiants

pubmed: 33995135
doi: 10.3389/fpsyt.2021.566091
pmc: PMC8115127
doi:

Types de publication

Journal Article

Langues

eng

Pagination

566091

Informations de copyright

Copyright © 2021 Sun, Bo, Mao, Li, He, Pao, Li, He, Ma and Wang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Inherit Metab Dis. 2021 May;44(3):554-565
pubmed: 33034372
Mol Neurobiol. 2019 Dec;56(12):8087-8100
pubmed: 31183808
Neurochem Res. 2018 Jun;43(6):1171-1181
pubmed: 29671235
Neural Regen Res. 2014 Apr 1;9(7):735-40
pubmed: 25206881
Biol Psychiatry. 1984 Oct;19(10):1395-402
pubmed: 6335052
Bipolar Disord. 2008 May;10(3):349-59
pubmed: 18402623
Curr Top Behav Neurosci. 2021;48:21-39
pubmed: 32748285
Psychopharmacology (Berl). 1976 Nov 24;50(3):259-67
pubmed: 826971
Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):88-90
pubmed: 16152569
Neuropsychopharmacology. 2011 Jul;36(8):1608-19
pubmed: 21471955
PLoS One. 2014 Jun 27;9(6):e100634
pubmed: 24971450
J Neurochem. 2014 Feb;128(3):445-58
pubmed: 24111919
Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):730-6
pubmed: 21761554
Rev Neurosci. 2019 May 27;30(4):381-426
pubmed: 30269107
Neuropsychobiology. 1978;4(4):248-55
pubmed: 652146
J Neurochem. 2020 Jan;152(2):157-181
pubmed: 31613389
Eur J Hum Genet. 2007 Aug;15(8):878-83
pubmed: 17457369
Biol Psychiatry. 2002 Mar 1;51(5):358-64
pubmed: 11904129
Soc Cogn Affect Neurosci. 2014 Sep;9(9):1341-5
pubmed: 23988761
Biol Psychiatry. 1999 Feb 15;45(4):448-52
pubmed: 10071716
Biol Psychiatry. 1982 Dec;17(12):1415-24
pubmed: 7159639
Cell Tissue Res. 2019 Jul;377(1):107-113
pubmed: 30627806
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):155-161
pubmed: 28647535
BMC Neurol. 2017 Nov 17;17(1):199
pubmed: 29149884
Neuroscience. 2019 Aug 1;412:175-189
pubmed: 31195057
Clin Exp Hypertens. 2020;42(2):118-125
pubmed: 30821508
Schizophr Res. 2018 Mar;193:58-63
pubmed: 28647493
Can J Neurol Sci. 1980 Aug;7(3):267-8
pubmed: 6108796
Pharmacol Biochem Behav. 2019 Mar;178:42-50
pubmed: 29289701
J Psychopharmacol. 2020 Mar;34(3):358-369
pubmed: 31913053
Front Psychiatry. 2018 Jun 13;9:253
pubmed: 29951006
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1214-24
pubmed: 16226365
Neuro Endocrinol Lett. 2009;30(5):604-9
pubmed: 20035263
Lancet. 2016 Apr 9;387(10027):1561-1572
pubmed: 26388529
Am J Psychiatry. 1965 Nov;122(5):509-22
pubmed: 5319766
Schizophr Res. 2008 Feb;99(1-3):111-8
pubmed: 18096371
Hum Genet. 2011 Nov;130(5):635-43
pubmed: 21509519
J Clin Psychiatry. 2010 May;71(5):599-605
pubmed: 20021991
Psychiatry Res. 1995 Nov 29;59(1-2):165-70
pubmed: 8771233
Brain Res. 2012 Jun 12;1459:91-9
pubmed: 22560594
Gynecol Endocrinol. 2020 Sep;36(9):786-790
pubmed: 31914838
Nature. 1995 Apr 13;374(6523):643-6
pubmed: 7715704
Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028
pubmed: 28160035
PLoS One. 2019 Feb 28;14(2):e0210175
pubmed: 30817802
Front Neurosci. 2017 May 01;11:243
pubmed: 28507504
Microbiologyopen. 2019 Apr;8(4):e00664
pubmed: 29897673
J Vis Exp. 2019 Mar 7;(145):
pubmed: 30907876
Front Hum Neurosci. 2018 Jun 21;12:202
pubmed: 29977196
Clin Neuropsychol. 2015;29 Suppl 1:1-18
pubmed: 25922131
Psychiatry Res. 2016 Dec 30;246:427-431
pubmed: 27788464
Brain Stimul. 2018 Jan - Feb;11(1):222-230
pubmed: 29074339
Psychogeriatrics. 2018 May;18(3):190-201
pubmed: 29423959
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Clin Exp Hypertens. 2020;42(2):181-189
pubmed: 30957546
Am J Hum Genet. 2001 Feb;68(2):515-22
pubmed: 11170900
Bipolar Disord. 2018 May;20(3):195-227
pubmed: 29441650
Int J Neuropsychopharmacol. 2018 Feb 1;21(2):108-113
pubmed: 29016993
Lancet. 2019 Jul 20;394(10194):240-248
pubmed: 31200992
Gene. 2013 May 1;519(2):356-9
pubmed: 23384717
Acta Psychiatr Scand. 1989 Nov;80(5):474-8
pubmed: 2596346
Clinicoecon Outcomes Res. 2020 Feb 07;12:81-89
pubmed: 32104020
Handb Clin Neurol. 2019;163:123-143
pubmed: 31590726
Neurosci Biobehav Rev. 2017 Jun;77:317-326
pubmed: 28342763
Front Behav Neurosci. 2018 Jul 02;12:129
pubmed: 30034328
J Mol Neurosci. 2015 Feb;55(2):367-71
pubmed: 24888991
Neural Plast. 2018 Jun 13;2018:1892570
pubmed: 30008741
Bipolar Disord. 2016 Aug;18(5):440-50
pubmed: 27566286
Curr Drug Targets. 2009 Nov;10(11):1061-8
pubmed: 19702556
Int J Neuropsychopharmacol. 2017 Dec 1;20(12):1036-1046
pubmed: 29106542
Mol Psychiatry. 2017 May;22(5):666-679
pubmed: 28289283
Psychopharmacology (Berl). 2020 Jul;237(7):1909-1915
pubmed: 32529266
Epilepsy Res. 2005 Jun;65(1-2):23-31
pubmed: 15955669
Asia Pac Psychiatry. 2015 Mar;7(1):78-84
pubmed: 24259452
Can J Physiol Pharmacol. 2019 Jul;97(7):685-690
pubmed: 30773040
Curr Biol. 2015 Nov 2;25(21):R1051-R1056
pubmed: 26528750
CNS Spectr. 2019 Feb;24(1):64-77
pubmed: 30472971
Pol J Pharmacol. 2004 Nov-Dec;56(6):825-9
pubmed: 15662096
J Neural Transm (Vienna). 2017 Sep;124(9):1135-1143
pubmed: 28656371
J Pharmacol Exp Ther. 2001 Aug;298(2):651-7
pubmed: 11454927

Auteurs

Zuoli Sun (Z)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Qijing Bo (Q)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Zhen Mao (Z)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Feng Li (F)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Fan He (F)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Christine Pao (C)

Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Wenbiao Li (W)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.

Yi He (Y)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Xin Ma (X)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Chuanyue Wang (C)

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Classifications MeSH